Drug Trial Radar · NCT05732155
Preliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 1, 2023
Primary completion
Jun 1, 2027
Study completion Jul 1, 2028
Sponsor
- Lead sponsor
- Guy SchusheimAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Resilient Pharmaceuticals
- First posted
- Feb 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of methylenedioxymethamphetaminel, in participants with war-related Post traumatic Stress Disorder, in a hybrid individual and group treatment protocol. The overall safety objective is to assess the severity, incidence, and frequency of AEs, AEs of Special Interest (AESIs), and Serious Adverse Events (SAEs), concomitant medication use, suicidal ideation and behavior and vital signs .
Conditions
- Post Traumatic Stress Disorder
- MDMA ('Ecstasy')
Interventions
methylenedioxymethamphetamineDrug
Participants in the experimental arm receive MDMA hydrochloride during three approximately 8-hour experimental sessions conducted within a manualized MDMA-assisted therapy protocol. Two sessions are delivered individually and one is delivered in a group setting. Each session includes an initial dose of MDMA hydrochloride followed by a planned supplemental half-dose approximately two hours later, unless the participant declines or tolerability concerns arise. MDMA administration is embedded within preparatory and integration psychotherapy delivered according to the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from pre-treatment baseline to post-treatment in CAPS-5 total scoreTime frame: From baseline to V18, approximately 18 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emek medical center
Afula, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.